Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6318426 | 0.91 | KCNH2 (0.46) | KCNH2MAPT | |
| SCHEMBL6319142 | 0.88 | KCNH2 (0.46) | KCNH2MAPTLMNA | |
| SCHEMBL6318334 | 0.81 | KCNH2 (0.53) | KCNH2MAPT | |
| SCHEMBL6318103 | 0.81 | KCNH2 (0.53) | KCNH2MAPT | |
| SCHEMBL6319636 | 0.81 | KCNH2 (0.48) | KCNH2MAPT | |
| SCHEMBL6318282 | 0.73 | KCNH2 (0.51) | KCNH2 | |
| SCHEMBL6320713 | 0.73 | KCNH2 (0.51) | KCNH2 | |
| SCHEMBL6318076 | 0.72 | KCNH2 (0.47) | KCNH2 | |
| SCHEMBL6325235 | 0.72 | KCNH2 (0.65) | KCNH2MAPT | |
| SCHEMBL6319481 | 0.72 | KCNH2 (0.65) | KCNH2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858568-B2 | Metal lubricants containing a bridge complex | MEC INTERNATIONAL CORPORATION (JP) | 2005-02-22 | — | — | US | claimed |
| US-20020123435-A1 | Metal lubricants containing a bridge complex | MEC INTERNATIONAL CORPORATION | 2002-09-05 | — | — | US | claimed |
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1472260-A2 | THIENO(3,2-B)PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003059878-A2 | THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IRF3, IFNAR1 | KCNH2 491/4885MAPT 3255/4885F10 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.